As BioNTech struggles to establish its footing in a post-pandemic world, the biotech has secured $145 million from the Coalition for Epidemic Preparedness Innovations to expand its mRNA operations in Rwanda.
As AstraZeneca looks to climb toward the top of biopharma companies by revenue by the end of the decade, smaller companies are looking to join the ranks of the unofficial Big Pharma club.
The European Patent Office last week upheld one of Moderna’s key patents, handing the biotech an important victory in its protracted COVID-19 vaccine battle with Pfizer and BioNTech.
Reeling from “endemic-level demand” for its COVID-19 vaccine, BioNTech on Monday reported a steep decline in revenues and a loss per share that fell short of analysts’ consensus estimates for the first quarter of 2024.
With its lawsuit filed against Pfizer and BioNTech, the British multinational biopharma has joined the high-profile patent battle over mRNA technology used in COVID-19 vaccines.
A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged patent infringement related to their COVID-19 vaccine Comirnaty.
See our latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
The National Institutes of Health claims BioNTech is in default regarding alleged royalty payments the agency contends it is owed in connection with the company’s COVID-19 vaccine Comirnaty.
Both Pfizer and Moderna surprised analysts with sales of COVID-19 vaccines and treatments, yet the companies still need to manage declining revenues in the years to come.
Genmab A/S and BioNTech SE announced initial data from the ongoing Phase 2 trial evaluating acasunlimab, an investigational bispecific antibody also known as GEN1046/BNT311, as monotherapy and in combination with pembrolizumab in patients with PD-L-positive metastatic non-small cell lung cancer who had disease progression following one or more prior lines of anti-PD1-containing treatment.
BioNTech SE and the Coalition for Epidemic Preparedness Innovations are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem.
BioNTech SE will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024.
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for solid tumors and BioNTech SE have announced that their collaboration to advance T cell receptor immunotherapies against cancer will extend beyond the initial three-year term outlined at the signing of the agreement in February 2022.
BioNTech SE held its Annual General Meeting , May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly.
BioNTech SE reported financial results for the three months ended March 31, 2024, and provided an update on its corporate progress.
BioNTech SE will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
BioNTech SE announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy candidate autogene cevumeran in patients with resected pancreatic ductal adenocarcinoma.
BioNTech SE reported financial results for the three months and full year ended December 31, 2023, and provided an update on its corporate progress.
BioNTech SE announced that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.